Lennox-Gastaut Syndrome Epidemiology Forecast Report, 2017-2030 - ResearchAndMarkets.com

The "Lennox-Gastaut Syndrome - Epidemiology Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.

This 'Lennox-Gastaut Syndrome (LGS)- Epidemiology Forecast - 2030' report delivers an in-depth understanding of the Lennox-Gastaut Syndrome (LGS), historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Lennox-Gastaut Syndrome (LGS) Epidemiology

The Lennox-Gastaut Syndrome (LGS) epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Lennox-Gastaut Syndrome (LGS) epidemiology segmented as the Total Prevalent cases of Lennox-Gastaut Syndrome (LGS), Diagnosed Prevalent Cases of Lennox-Gastaut Syndrome (LGS), Gender-Specific cases of Lennox-Gastaut Syndrome (LGS), Seizure-Specific cases of Lennox-Gastaut Syndrome (LGS). The report includes the Prevalent scenario of Lennox-Gastaut Syndrome (LGS) symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Country-wise- Lennox-Gastaut Syndrome (LGS) Epidemiology

The epidemiology segment also provides the Lennox-Gastaut Syndrome (LGS) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The total prevalent population of Lennox-Gastaut Syndrome (LGS) Associated in 7MM countries estimated to be 111,798 cases in 2017.

• As per the estimates, the United States has the highest Prevalent population of Lennox-Gastaut Syndrome (LGS)
• Among the EU5 countries, Germany had the highest prevalent population of Lennox-Gastaut Syndrome (LGS). On the other hand, Spain had the lowest prevalent population, with 8,323 cases in 2017.

Report Highlights

• 11-Year Forecast of Lennox-Gastaut Syndrome (LGS) epidemiology
• 7MM Coverage
• Total Prevalent Cases of Lennox-Gastaut Syndrome (LGS)
• Prevalent cases according to segmentation: Gender-specific Prevalence of Lennox-Gastaut Syndrome (LGS), Seizure-specific Prevalence of Lennox-Gastaut Syndrome (LGS).

KOL Views

The publisher interviews KOLs, and SME's opinion through primary research to fill the data gaps and validate the secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

• What will be the growth opportunities in the 7MM concerning the patient population about Lennox-Gastaut Syndrome (LGS)?
• What are the key findings of Lennox-Gastaut Syndrome (LGS) epidemiology across 7MM, and which country will have the highest number of patients during the forecast period (2017-2030)?
• What would be the total number of patients of Lennox-Gastaut Syndrome (LGS) across the 7MM during the forecast period (2017-2030)?
• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
• What are the disease risk, burden, and unmet needs of Lennox-Gastaut Syndrome (LGS)?
• What are the currently available treatments for Lennox-Gastaut Syndrome (LGS)?

Key Assessments

• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Geographies Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2017-2030

The US's epidemiological model is based on the assumption based as per Lennox-Gastaut Foundation 2016. The organization revealed that there are approximately 14,000-18,000 children with LGS under 18 years in the United States, accounting for about 40% of cases from children, and the rest 60% of cases belong to adults.

Key Topics Covered:

1. Key Insights

2. Lennox-Gastaut Syndrome (LGS): Epidemiology Overview at a Glance

2.1. Patient Share (%) Distribution of LGS in 2017

2.2. Patient Share (%) Distribution of LGS in 2030

3. Executive summary

4. Organizations

5. Disease Overview: Lennox-Gastaut Syndrome (LGS)

5.1. Introduction

5.2. Classification

5.3. Signs and Symptoms

5.4. Types of Seizures associated with LGS

5.5. Etiology

5.6. Pathogenesis

5.7. Diagnosis

5.7.1. Differential Diagnosis

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. 7MM Total Prevalent Patient Population of Lennox-Gastaut Syndrome (LGS)

6.3. 7MM Total Diagnosed Prevalent Patient Population of Lennox-Gastaut Syndrome (LGS)

6.4. Country-wise Epidemiology of Lennox-Gastaut Syndrome (LGS)

6.5. United States

6.5.1. Assumptions and Rationale

6.5.2. Total Prevalent Cases of Lennox-Gastaut Syndrome in the United States

6.5.3. Diagnosed Prevalent Cases of Lennox-Gastaut Syndrome in the United States

6.5.4. Gender-specific Diagnosed Prevalent Cases of LGS in the United States

6.5.5. Seizure-specific Diagnosed Prevalent Cases of LGS in the United States

6.6. Germany

6.7. France

6.8. Italy

6.9. Spain

6.10. United Kingdom

6.11. Japan

7. Current Treatment Practices

7.1. Treatment Algorithm

7.2. Treatment Guidelines

7.2.1. NICE Guidelines

7.2.2. American Academy of Neurology (AAN)

8. Unmet needs

9. SWOT Analysis

10. Case studies

10.1. Epilepsy in Christianson syndrome: Case of Lennox-Gastaut syndrome

10.2. A Case of Lennox-Gastaut Syndrome in a 6-Year-Old Child with Moyamoya Disease

11. KOL Views

12. Appendix

For more information about this report visit https://www.researchandmarkets.com/r/8kfs8h

View source version on businesswire.com: https://www.businesswire.com/news/home/20210106005542/en/